{"meta":{"totalResults":2,"from":0},"results":[{"aliases":[{"type":"ObsoleteName","name":"HuMax-CD38"},{"type":"Synonym","name":"anti-CD38 monoclonal antibody"},{"type":"USBrandName","name":"Darzalex"},{"type":"CASRegistryName","name":"945721-28-8"},{"type":"CodeName","name":"JNJ-54767414"},{"type":"Synonym","name":"daratumumab biosimilar HLX15"},{"type":"CodeName","name":"HLX15"}],"definition":{"html":"A human immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, with immunomodulating and antineoplastic activities. Upon administration, daratumumab targets and binds to CD38 expressed on tumor cells. This triggers direct cell killing, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell mediated phagocytosis (ADCP) and antibody-mediated complement dependent cytotoxicity (CDC) in CD38-expressing tumor cells. In addition, binding to CD38 by daratumumab depletes CD38-expressing immunosuppressive regulatory T  and B cells and myeloid-derived suppressor cells (MDSCs). CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.","text":"A human immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, with immunomodulating and antineoplastic activities. Upon administration, daratumumab targets and binds to CD38 expressed on tumor cells. This triggers direct cell killing, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell mediated phagocytosis (ADCP) and antibody-mediated complement dependent cytotoxicity (CDC) in CD38-expressing tumor cells. In addition, binding to CD38 by daratumumab depletes CD38-expressing immunosuppressive regulatory T  and B cells and myeloid-derived suppressor cells (MDSCs). CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/daratumumab","text":"Daratumumab"},"nciConceptId":"C74007","nciConceptName":"Daratumumab","termId":583564,"name":"daratumumab","firstLetter":"d","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"daratumumab"},{"aliases":[{"type":"Synonym","name":"darzalex/rHuPH20"},{"type":"Synonym","name":"daratumumab-rHuPH20"},{"type":"Synonym","name":"daratumumab/rHuPH20 co-formulation"},{"type":"Synonym","name":"DARA/rHuPH20"},{"type":"Synonym","name":"daratumumab with rHuPH20"},{"type":"Synonym","name":"HuMax-CD38-rHuPH20"},{"type":"Synonym","name":"daratumumab + rHuPH20"},{"type":"Synonym","name":"recombinant human hyaluronidase mixed with daratumumab"},{"type":"Synonym","name":"DARA co-formulated with rHuPH20"},{"type":"USBrandName","name":"Darzalex Faspro"},{"type":"Synonym","name":"daratumumab and hyaluronidase"},{"type":"Synonym","name":"daratumumab/hyaluronidase-fihj"}],"definition":{"html":"A co-formulation composed of daratumumab, a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against the cell surface glycoprotein cluster of differentiation 38 (CD-38; CD38), and a recombinant form of human hyaluronidase (rHuPH20), with potential antineoplastic activity. Upon subcutaneous administration of daratumumab and hyaluronidase-fihj, daratumumab targets and binds to CD38 on certain CD38-expressing tumors, such as multiple myeloma (MM) and plasma cell leukemia. This binding induces direct apoptosis through Fc-mediated cross-linking and triggers immune-mediated tumor cell lysis through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP) immune responses. CD38, a transmembrane glycoprotein, is expressed in both hematopoietic and non-hematopoietic lineage cells. Hyaluronidase-fihj hydrolyzes and degrades the glycosaminoglycan hyaluronic acid (HA), thereby decreasing interstitial viscosity and enhancing penetration of daratumumab through the interstitial space. This facilitates the delivery of daratumumab to CD38-expressing tumor cells.","text":"A co-formulation composed of daratumumab, a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against the cell surface glycoprotein cluster of differentiation 38 (CD-38; CD38), and a recombinant form of human hyaluronidase (rHuPH20), with potential antineoplastic activity. Upon subcutaneous administration of daratumumab and hyaluronidase-fihj, daratumumab targets and binds to CD38 on certain CD38-expressing tumors, such as multiple myeloma (MM) and plasma cell leukemia. This binding induces direct apoptosis through Fc-mediated cross-linking and triggers immune-mediated tumor cell lysis through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP) immune responses. CD38, a transmembrane glycoprotein, is expressed in both hematopoietic and non-hematopoietic lineage cells. Hyaluronidase-fihj hydrolyzes and degrades the glycosaminoglycan hyaluronic acid (HA), thereby decreasing interstitial viscosity and enhancing penetration of daratumumab through the interstitial space. This facilitates the delivery of daratumumab to CD38-expressing tumor cells."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/daratumumabandhyaluronidase-fihj","text":"Daratumumab and Hyaluronidase-fihj"},"nciConceptId":"C156401","nciConceptName":"Daratumumab and Recombinant Human Hyaluronidase","termId":795698,"name":"daratumumab and hyaluronidase-fihj","firstLetter":"d","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"daratumumab-and-recombinant-human-hyaluronidase"}],"links":null}